

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Rathi 1



Section 1.	Identifying Inform	nation	
1. Given Name (Fi Nityam	rst Name)	2. Surname (Last Name) Rathi	3. Date 14-December-2020
4. Are you the cor	responding author?	Yes ✓ No	Corresponding Author's Name
5. Manuscript Title The tango of imr		eted therapy in metastatic	renal cell carcinoma
6. Manuscript Ider	ntifying Number (if you kr	now it)	
			-
Section 2.	The Work Under Co	onsideration for Public	ntion
any aspect of the s statistical analysis,	stitution at any time rece ubmitted work (including	ive payment or services from but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3.	Relevant financial	activities outside the s	ubmitted work.
of compensation clicking the "Add	n) with entities as descri	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount e one line for each entity; add as many lines as you need by e present during the 36 months prior to publication .
Section 4.	Intellectual Proper	rty Patents & Copyric	yhts
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No

Rathi 2



Section 5.	
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	ationships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements Irnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Nityam Rathi ha	s nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Rathi 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



Continu 1						
Section 1. Identifying Inform	ation					
Given Name (First Name) Benjamin	2. Surname (Last Name Maughan	•)	3. Date 14-December-2020			
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Au Neeraj Agarwal	uthor's Name			
5. Manuscript Title The tango of immunotherapy and targe	eted therapy in metasta	atic renal cell carcinor	ma			
6. Manuscript Identifying Number (if you kn	now it)					
Section 2. The Work Under Co	onsideration for Pub	olication				
			nment commercial private foundation etc.) for			
any aspect of the submitted work (including			nment, commercial, private foundation, etc.) for d, study design, manuscript preparation,			
statistical analysis, etc.)? Are there any relevant conflicts of intere	est? ✓ Yes No	0				
•			entity press the "ADD" button to add a row.			
Excess rows can be removed by pressing						
Name of Institution/Company	Grant? Personal Fees?	Non-Financial Othe	Comments			
xelixis	V		Advisory Board Member and recepit of funding for clinical trial			
anssen			Advisory Board Member			
1erck			Advisory Board Member			
VEO Oncology			Advisory Board Member			
Section 3. Polevant financial	activities outside th	e submitted work				
Nelevalit illialitial	activities outside til	e subilitted work	•			
	ibed in the instructions.	. Use one line for each	ancial relationships (regardless of amount n entity; add as many lines as you need by the 36 months prior to publication.			
Are there any relevant conflicts of interest? Ves No						
If yes, please fill out the appropriate info						



Name of Entity	Grant?	Personal	Non-Financial	Other?	Comments
Astellas		Fees	Support	√	Advisory Board Member
BMS				▼	Advisory Board Member
Clovis Oncology				▼	Advisory Board Member
Tempus				▼	Advisory Board Member
Bayer Oncology				▼	Advisory Board Member
Peloton Therapeutics				▼	Advisory Board Member
Bavarian-Nordic	□				Receipt of funding for a clinical trial
Section 4. Intellectual Propert	y Pate	ents & Cop	oyrights		
Section 5. Relationships not covered above Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.					
Disclosure Stateme		11			
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below. Dr. Maughan reports grants and other from Exelixis, other from Janssen, other from Merck, other from AVEO Oncology, during the conduct of the study; other from Astellas, other from BMS, other from Clovis Oncology, other from Tempus, other from Bayer Oncology, other from Peloton Therapeutics, grants from Bavarian-Nordic, outside the submitted work; .					



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Agarwal

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

1

administrative support, etc.



Section 1. Identifying Information	ation						
1. Given Name (First Name) Neeraj	2. Surnar Agarwal	ne (Last Nai	ne)		3. Date 14-December-2020		
4. Are you the corresponding author?	e corresponding author? Yes No						
5. Manuscript Title The tango of immunotherapy and targe	ted thera _l	oy in meta	static renal cell ca	rcinoma			
6. Manuscript Identifying Number (if you kno	ow it)						
Section 2. The Work Under Co	nsidera	tion for P	ublication				
Did you or your institution at any time receivany aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interests	but not lin		nts, data monitoring				
Section 3. Relevant financial a	ctivities	outside	the submitted	work.			
Place a check in the appropriate boxes ir of compensation) with entities as describ clicking the "Add +" box. You should rep Are there any relevant conflicts of interes	oed in the ort relatio	instructio onships tha	ns. Use one line fo	or each er	ntity; add as many lines as you need by		
If yes, please fill out the appropriate info	rmation b	elow.					
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
Astellas		✓		✓	Advisory Board, Honoraria		
Astra Zeneca	✓	✓		✓	Advisory Board, Honoraria, Research Funding		
Bavarian Nordic	√				Research Funding		
Bayer	✓	✓		✓	Advisory Board, , HonorariaResearch Funding		
BN immunotherapeutics	✓				Research Funding		
Bristol Myers Squibb	✓	✓		✓	Advisory Board, Honoraria, Research		



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Calithera	✓	✓			Advisory Board, Honoraria, Research Funding
Celldex	✓				Research Funding
Clovis	✓	✓			Advisory Board, Honoraria Research Funding
Eisai	✓	✓		✓	Advisory Board, Honoraria, Funding
Eli Lilly	✓	✓			Advisory Board, Honoraria, Research Funding
EMD Serono	✓	✓			Advisory Board, Honoraria, Research Funding
exelixis	✓	✓			Advisory Board, Honoraria, Research Funding
Foundation Medicine		√		✓	Advisory Board, Honoraria
Genentech	✓	✓			Advisory Board, Honoraria, Research Funding
Glaxo Smith Kline	✓				Research Funding
mmunomedics	✓				Research Funding
lanssen	✓	✓			Advisory Board, Honoraria, Research Funding
Medivation	✓				Research Funding
Merck	✓	✓			Advisory Board, Honoraria, Research Funding
Nektar	✓	✓			Advisory Board, Honoraria, Research Funding
New Link Genetics	✓				Research Funding
Novartis	✓	✓		√	Advisory Board, Honoraria, Research Funding
Pfizer	✓	✓			Advisory Board, Honoraria, Research Funding
Pharmacyclics		✓		✓	Advisory Board, Honoraria
Prometheus	✓				Research Funding
Rexahn	✓				Research Funding
Roche	✓				Research Funding
Sanofi	✓				Research Funding
Seattle Genetics	✓	✓			Advisory Board, Honoraria, Research Funding
Гаkeda	✓				Research Funding



Tracon		✓				Research Funding		
Aveo	Advisory Board, Honoraria							
MEI Pharma	Advisory Board, Honoraria							
Section 4.	Intellectual Proper	ty Dates	ate & Con	vyiahta				
	intellectual Proper	ty Patei	its & Cop	lyrights				
Do you have any	patents, whether plani	ned, pendir	ng or issue	d, broadly releva	nt to the	e work? Yes 🗸 No		
						<u> </u>		
Section 5.								
Section 5.	Relationships not	covered a	bove					
	-				nfluence	ed, or that give the appearance of		
potentially influe	encing, what you wrote	in the subn	nitted wor	k?				
□ Vos. the follo	wing relationships/con	ditions/circ	umstanco	s are present love	alain hal	owl:		
✓ No other rela	tionships/conditions/ci	rcumstance	es that pre	sent a potential c	conflict (of interest		
At the time of m	anuscrint accentance id	ournals will	ask autho	rs to confirm and	l if nece	ssary, update their disclosure statements.		
	rnals may ask authors to					•		
Section 6.	Disclosure Stateme	ent						
						<u> </u>		

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Agarwal reports personal fees and other from Astellas, grants, personal fees and other from Astra Zeneca, grants from Bavarian Nordic, grants, personal fees and other from Bayer, grants from BN immunotherapeutics, grants, personal fees and other from Bristol Myers Squibb, grants, personal fees and other from Calithera, grants from Celldex, grants, personal fees and other from Clovis, grants, personal fees and other from Eisai, grants, personal fees and other from Eli Lilly, grants, personal fees and other from EMD Serono, grants, personal fees and other from Exelixis, personal fees and other from Foundation Medicine, grants, personal fees and other from Genentech, grants from Glaxo Smith Kline, grants from Immunomedics, grants, personal fees and other from Janssen, grants from Medivation, grants, personal fees and other from Merck, grants, personal fees and other from New Link Genetics, grants, personal fees and other from Novartis, grants, personal fees and other from Prometheus, grants from Rexahn, grants from Roche, grants from Sanofi, grants, personal fees and other from Seattle Genetics, grants from Takeda, grants from Tracon, personal fees and other from Aveo, personal fees and other from MEI Pharma, outside the submitted work.



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Swami 1



Section 1.	Identifying Inform	ation		
1. Given Name (Fii Umang	rst Name)	2. Surname (Last Name) Swami	3. Date 14-December-2020	
4. Are you the cor	responding author?	✓ Yes No		
5. Manuscript Title The tango of imr		ted therapy in metastatic renal ce	ell carcinoma	
6. Manuscript Ider	ntifying Number (if you kn	ow it)		
Section 2.	The Work Under Co	onsideration for Publication		
any aspect of the s statistical analysis,	stitution at any time recei ubmitted work (including	ve payment or services from a third p but not limited to grants, data monit		ommercial, private foundation, etc.) for esign, manuscript preparation,
Section 3.	Relevant financial	activities outside the submit	ted work.	
of compensation clicking the "Add	n) with entities as descri	bed in the instructions. Use one lip port relationships that were prese	ne for each entity; a	lationships (regardless of amount add as many lines as you need by months prior to publication.
Section 4.				
	Intellectual Proper	ty Patents & Copyrights		
Do you have any	patents, whether plani	ned, pending or issued, broadly re	levant to the work	? ☐ Yes ✓ No

Swami 2



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Swami has n	othing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Swami 3